News
ACOG
6.10
+6.56%
0.38
Alpha Cognition, China Medical System enter exclusive Zunveyl licensing pact
TipRanks · 3d ago
Alpha Cognition Inks $44 Million Licensing Pact For Its Alzheimer's Drug In China
Benzinga · 3d ago
Alpha Cognition announces $44M licensing agreement for commercialization of ZUNVEYL in China
Seeking Alpha · 3d ago
ALPHA COGNITION ANNOUNCES A $44 MILLION EXCLUSIVE LICENSING AGREEMENT FOR THE DEVELOPMENT AND COMMERCIALIZATION OF ZUNVEYL (BENZGALANTAMINE), AN FDA-APPROVED TREATMENT FOR MILD-TO-MODERATE ALZHEIMER’S DISEASE, IN CHINA
Reuters · 3d ago
ALPHA COGNITION INC: REMAINS ON TRACK TO LAUNCH ZUNVEYL IN UNITED STATES IN Q1 2025
Reuters · 3d ago
Weekly Report: what happened at ACOG last week (1230-0103)?
Weekly Report · 5d ago
Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimer’s Long-Term Care Market During Investor Update Call
Barchart · 5d ago
Alpha Cognition files to sell 1.45M common shares for holders
TipRanks · 12/31/2024 22:05
ALPHA COGNITION- FILES PROSPECTUS COVERING UP TO 1.45 MLN COMMON SHARES THAT MAY BE OFFERED FOR RESALE/OTHERWISE DISPOSED OF BY SELLING STOCKHOLDERS
Reuters · 12/31/2024 22:01
Weekly Report: what happened at ACOG last week (1223-1227)?
Weekly Report · 12/30/2024 10:43
Weekly Report: what happened at ACOG last week (1216-1220)?
Weekly Report · 12/23/2024 10:48
Alpha Cognition Raises $52.8 Million in Stock Offering
TipRanks · 12/16/2024 23:07
Alpha Cognition Reports Promising Data for Brain Injury Drug
TipRanks · 12/16/2024 18:37
Alpha Cognition Announces Partial Exercise of Over-allotment Option
Barchart · 12/16/2024 13:56
Weekly Report: what happened at ACOG last week (1209-1213)?
Weekly Report · 12/16/2024 10:49
Alpha Cognition to delist from Canadian Securities Exchange
Seeking Alpha · 12/13/2024 11:13
Alpha Cognition voluntarily delisting from Canadian Securities Exchange
TipRanks · 12/12/2024 23:45
ALPHA COGNITION ANNOUNCES VOLUNTARY DELISTING FROM CSE
Reuters · 12/12/2024 23:41
Alpha Cognition: Data support ALPHA-1062 develpment for militaryTBI treatment
TipRanks · 12/11/2024 13:50
Weekly Report: what happened at ACOG last week (1202-1206)?
Weekly Report · 12/09/2024 10:48
More
Webull provides a variety of real-time ACOG stock news. You can receive the latest news about Alpha Cognition through multiple platforms. This information may help you make smarter investment decisions.
About ACOG
Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062 is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS.